Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG409

—

1bd0e6fd-c2c3-518b-a535-639bf29444d7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.525
  • E2F_TARGETS+0.519
  • MYC_TARGETS_V1+0.519
  • MITOTIC_SPINDLE+0.426
  • ANGIOGENESIS+0.384
  • OXIDATIVE_PHOSPHORYLATION+0.358
  • MYC_TARGETS_V2+0.355
  • UNFOLDED_PROTEIN_RESPONSE+0.347
  • MTORC1_SIGNALING+0.337
  • PROTEIN_SECRETION+0.312

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.425
  • INTERFERON_GAMMA_RESPONSE-0.419
  • ALLOGRAFT_REJECTION-0.367
  • INFLAMMATORY_RESPONSE-0.317
  • IL6_JAK_STAT3_SIGNALING-0.313
  • BILE_ACID_METABOLISM-0.234
  • KRAS_SIGNALING_DN-0.173
  • COMPLEMENT-0.170
  • APOPTOSIS-0.131
  • COAGULATION-0.129

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG169
mng-umap@100
——0.892
2BS_4SCWT0FX
brain-umap@2
Ependymoma NOS—0.885
3MNG257
mng-umap@100
——0.883
4MNG1179
mng-umap@100
——0.877
5BS_P7EY9DXG
brain-umap@2
ATRT—0.871
6MNG1011
mng-umap@100
——0.866
7C3L-00081
lung-landscapes@6
—cohortSQ20.861
8a7e776a3-4159-4cf7-8e05-2c2202330f58
melanoma-umap@29
——0.859
9AUR-AE6Y-TTM1-A-1-1-R-A742-41
breast-umap@18
—E0.857
10TCGA-BT-A20N-01A-11R-A14Y-07
bladder-landscape@3
——0.855

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.525Inavolisib— uncovered
E2F_TARGETS0.519Inavolisib— uncovered
MYC_TARGETS_V10.519Inavolisib— uncovered
MITOTIC_SPINDLE0.426Inavolisib— uncovered
ANGIOGENESIS0.384Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.358Remibrutinib— uncovered
MYC_TARGETS_V20.355Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.347Idelalisib— uncovered
MTORC1_SIGNALING0.337Inavolisib— uncovered
PROTEIN_SECRETION0.312Remibrutinib— uncovered
GLYCOLYSIS0.294Inavolisib— uncovered
NOTCH_SIGNALING0.282Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.224Remibrutinib— uncovered
DNA_REPAIR0.223Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.176Inavolisib— uncovered
HYPOXIA0.160Idelalisib— uncovered
UV_RESPONSE_UP0.125Idelalisib— uncovered
UV_RESPONSE_DN0.106Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.083Inavolisib— uncovered
ADIPOGENESIS0.082Inavolisib— uncovered